ICON’s novel RNA-based NGS assay, Dup-Seq BCR::ABL1, represents a significant advancement in the management of CML patients.

Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

More than $994 million has been raised by Cambridge technology companies in the past 12 months (to October 16, 2024) – helped ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML) in patient samples. Researchers at Dana-Farber Cancer ...

Their work can help to lower the ... The Evolution of Green Energy Technology: Developing Three-Dimensional Smart Energy Devices With Radiant Cooling and Solar Absorption Oct. 25, 2024 — - DGIST ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML) in patient samples. Precision medicines have long been ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In the case of CML, a disease in which patients have too many immature white blood cells in their bone marrow and blood, a complete hematologic response occurs when the patient's white blood cell ...

Novartis has received FDA accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Ph+ CML-CP.

A key gene that could enhance the treatment success rates of chronic myeloid leukemia (CML) has been discovered by researchers. Professor Hongtae Kim and his research team in the Department of ...

Developed by Ascentage Pharma, olverembatinib is the first China -approved third-generation BCR:ABL1 inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent ...